Celon Pharma S.A.

WSE:CLN Stock Report

Market Cap: zł1.1b

Celon Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of CLN?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders5,7570.0107%
Institutions9,696,04218%
General Public14,127,17026.2%
Private Companies30,027,53155.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 20 shareholders own 73.77% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
55.8%
Glatton Sp. z o.o.
30,027,531zł592.1m0%no data
7.68%
Tang Capital Management, LLC
4,137,000zł81.6m0%0.97%
7.58%
Generali Powszechne Towarzystwo Emerytalne S A
4,083,585zł80.5m0%0.25%
0.77%
Towarzystwo Funduszy Inwestycyjnych Allianz Polska S.A.
413,554zł8.2m0%0.15%
0.63%
Goldman Sachs Towarzystwo Funduszy Inwestycyjnych S.A.
338,308zł6.7m0%0.07%
0.52%
Pekao Towarzystwo Funduszy Inwestycyjnych S.A.
281,304zł5.5m0%0.11%
0.25%
Skarbiec TFI S.A.
134,489zł2.7m0%0.07%
0.21%
Dimensional Fund Advisors LP
114,703zł2.3m0%no data
0.16%
Goldman Sachs Asset Management, L.P.
83,642zł1.6m0%no data
0.075%
Erste Towarzystwo Funduszy Inwestycyjnych S.A.
40,549zł799.6k0%0.01%
0.044%
Towarzystwo Funduszy Inwestycyjnych PZU SA
23,500zł463.4k0%no data
0.022%
State Street Global Advisors, Inc.
12,080zł238.2k-6.61%no data
0.02%
Alior Towarzystwo Funduszy Inwestycyjnych S.A.
11,000zł216.9k0%0.07%
0.017%
PKO Towarzystwo Funduszy Inwestycyjnych SA
9,000zł177.5k0%no data
0.011%
Artur Wieczorek
5,757zł113.5k0%no data
0.01%
Rockbridge TFI S.A.
5,608zł110.6k0%0.02%
0.009%
BNPP Asset Management Holding
4,853zł95.7k0%no data
0.0037%
BPS TFI SA
2,000zł39.4k0%0.15%
0.0012%
Superfund Towarzystwo Funduszy Inwestycyjnych S.a.
657zł13.0k0%0.01%
0.00039%
Towarzystwo Funduszy Inwestycyjnych S.A
210zł4.1k0%0.06%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/30 22:51
End of Day Share Price 2026/06/30 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Celon Pharma S.A. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Beata Szparaga-WasniewskaBiuro maklerskie mBanku
Tomasz SokolowskiErste Bank Polska S.A.
Piotr ZielonkaErste Bank Polska S.A.